Development and validation of T-ARMS-PCR to detect CYP2C19*17 allele.

Chenxi Jin,Zhikun Li,Xiaodi Zheng,Kailin Shen,Jiashuo Chao,Yifei Dong,Qin Huang,Qiulin Yin,Yan Deng,Weifeng Zhu
DOI: https://doi.org/10.1002/jcla.23005
IF: 3.124
2020-01-01
Journal of Clinical Laboratory Analysis
Abstract:Background CYP2C19*17 (rs12248560) is a functional single nucleotide polymorphism (SNP) in the CYP2C19 gene. It has been shown that CYP2C19*17 is associated with the clinical outcome of some drugs metabolized by CYP2C19 and a decreased risk of some diseases. The aim of this study was to develop a reliable and simple method to detect this polymorphism. Methods Tetra-primer amplification refractory mutation system-polymerase chain reaction (T-ARMS-PCR) was used to detect the CYP2C19*17 polymorphism. A total of 93 samples were screened by this method, and the results of T-ARMS-PCR were validated by DNA sequencing. Results There were 91 samples with the CC genotype (97.8%) and two samples with the CT genotype (2.2%). The frequency of the C allele was 98.9%, and the frequency of the T allele was 1.1%. The DNA sequencing results were completely concordant with the T-ARMS-PCR results. Conclusion T-ARMS-PCR can detect the CYP2C19*17 polymorphism with high accuracy, low costs, and a simple process.
What problem does this paper attempt to address?